Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II Trial of Axitinib (AG-013736) After Prior Antiangiogenic Therapy in Advanced Hepatocellular Carcinoma

NCT01334112 is registered in ClinicalTrials.gov with University Health Network, Toronto as lead sponsor.

NCT NCT01334112
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01334112 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II Trial of Axitinib (AG-013736) After Prior Antiangiogenic Therapy in Advanced Hepatocellular Carcinoma
Lead sponsor
University Health Network, Toronto
Phase
Phase 2
Overall status
Completed
Start date
January 31, 2011
Completion date
March 31, 2018
Enrollment
30 (actual)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

hepatocellular carcinoma